Markets:

Overview

News

Currencies

International

Treasuries

Novartis AG Common Stock (NY:NVS)

148.67 +2.25 (+1.54%)

Streaming Delayed Price Updated: 11:49 AM EDT, Jun 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Novartis AG Common Stock

< Previous 1 2

...

7 8 9 10 11 12 13 14 15

...

57 58 Next >

Pfizer's Ascent Signals Broader Health Sector Resilience Amidst Innovation Wave

August 04, 2025

In a notable shift, shares of Pfizer (NYSE: PFE) have recently edged higher, reflecting a burgeoning strength within the broader health sector. This uptick signals a renewed investor confidence in the...

Via MarketMinute

Trump Turns Up Heat On Big Pharma CEOs To Slash Drug Prices Within 60 Days — But Retail Traders Don't Flinch ↗

July 31, 2025

Via Stocktwits

Topics Government

Hazelden Betty Ford Foundation Appoints Four New Members to Its Board of Trustees

July 31, 2025

Center City, Minnesota--(Newsfile Corp. - July 31, 2025) - Hazelden Betty Ford Foundation, the nation's leading nonprofit system of addiction...

Via Newsfile

Earnings Outlook For Novartis ↗

July 16, 2025

Via Benzinga

Novartis Fails To Block Heart Failure Drug’s Generic From Launching Through 2026: Report ↗

July 11, 2025

Via Stocktwits

How Do Investors Really Feel About Novartis? ↗

July 10, 2025

Via Benzinga

15 regions chosen for groundbreaking effort to reduce cardiovascular disease

July 28, 2025

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

3 Pharma Stocks That Aren't Sweating the Coming 200% Drug Tariffs ↗

July 25, 2025

US President Trump imposed 200% tariff on pharmaceuticals affecting US drug prices and supply chain, but analysts say it may not happen soon.

Via Benzinga

Topics Economy Government World Trade

Sarepta Gets Thumbs Down From Regulators Regarding Elevidys Gene Therapy ↗

July 25, 2025

Sarepta and Roche face a regulatory setback as the EMA's CHMP issues a negative opinion on Elevidys for Duchenne muscular dystrophy patients.

Via Benzinga

U.S. Current-Account Deficit Widens to $450 Billion Amid Trade Imbalances and Energy Imports

July 25, 2025

The United States current-account deficit expanded sharply to $450 billion in the first half of 2025, marking a renewed widening of the country's financial shortfall with the rest of the world. This...

Via MarketMinute

Topics Artificial Intelligence Economy Supply Chain

NOVARTIS AG-SPONSORED ADR (NYSE:NVS): A Top Dividend Stock with Strong Profitability and Financial Stability ↗

July 25, 2025

NOVARTIS AG (NVS) is a top dividend stock with a 3.76% yield, strong profitability, and financial stability, making it ideal for income-focused investors.

Via Chartmill

The Hits Keep Coming For Sarepta. Why Its Latest Setback Creates A 'Dangerous Precedent' For Gene Therapies. ↗

July 24, 2025

Sarepta stock is now trading at a nine-year low as the debacle with its gene therapy, Elevidys, continues.

Via Investor's Business Daily

Topics Death Workforce

Screening for cardiovascular disease marker in community health centers may reduce risk

July 23, 2025

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Trump Tariffs Forces AstraZeneca To Bring Substantial Pharmaceutical Production To US ↗

July 22, 2025

AstraZeneca plans a $50 billion investment in U.S. facilities by 2030, including a Virginia plant focused on weight loss and metabolic drugs.

Via Benzinga

Topics Government

Highest Ever for This International Stock ETF -- But Analysts Say It Has Room to Run ↗

July 22, 2025

Via The Motley Fool

Topics ETFs World Trade

AstraZeneca Bets Big On America With $50B Investment, New Virginia Hub Plans Amid Pharma Tariff Jitters ↗

July 21, 2025

At the center of the company’s plan is a new, multi-billion-dollar manufacturing facility in Virginia.

Via Stocktwits

Topics Artificial Intelligence Government World Trade

Industry-Wide Tariffs Loom Over the Healthcare Sector. Here Are 2 Stocks That Can Weather the Storm. ↗

July 20, 2025

Via The Motley Fool

Topics Government World Trade

NOVARTIS AG-SPONSORED ADR (NYSE:NVS) – A Potentially Undervalued Stock With Strong Fundamentals ↗

July 19, 2025

NOVARTIS AG (NYSE:NVS) presents a value opportunity with strong profitability, financial health, and reasonable growth, trading below industry and market valuations.

Via Chartmill

Novartis Makes A Bearish Move As One Of Its Bread-And-Butter Drugs Misses ↗

July 17, 2025

The company's second biggest product missed sales expectations. Shares look likely to undercut a buy zone.

Via Investor's Business Daily

Topics Government Stocks

Novartis Trims Operating Income Outlook After Strong Q2 Performance, Initiates $10 Billion Stock Buyback ↗

July 17, 2025

Novartis posts solid Q2 results, raises 2025 earnings outlook, launches $10 billion share buyback, and announces CFO succession plan amid strong drug sales.

Via Benzinga

Earnings Scheduled For July 17, 2025 ↗

July 17, 2025

Via Benzinga

Trump's Pharma Tariffs Can Hit Novo Nordisk, Says Barclays Expert, But It's 'Difficult' To Predict As Drugmakers Have 'Complex Supply Chains' ↗

July 16, 2025

Barclays has said that it's hard to predict which firm would be affected the most by pharma tariffs, except for Novo Nordisk.

Via Benzinga

Topics Government World Trade

Divi’s Labs Shares Dip After Patent Loss: SEBI RA Recommends Buy On Dips ↗

July 14, 2025

The stock slid to an intraday low of ₹6,545 on Monday following a gap-down open, as investors reacted to MSN’s legal win over Entresto.

Via Stocktwits

Topics Intellectual Property

This Dividend ETF Is Near Its Highest Level Ever -- Is It Too Late to Invest in It? ↗

July 12, 2025

Via The Motley Fool

Topics ETFs

Pfizer, Astellas Report Xtandi Survival Win In Prostate Cancer Study ↗

July 10, 2025

Xtandi plus leuprolide improved overall survival in prostate cancer patients in the Phase 3 EMBARK trial, with no new safety concerns reported.

Via Benzinga

Novartis Gets Swiss Approval For First Malaria Drug For Babies ↗

July 08, 2025

Novartis' Coartem Baby wins Swiss approval as the first malaria drug for newborns under 5 kg, offering safer dosing and easier administration.

Via Benzinga

Novartis Gets Swiss Authority Nod For First Malaria Drug In Newborns, Young Infants ↗

July 08, 2025

The company said that it now expects rapid approval for the treatment in eight African countries, including Burkina Faso, Côte d'Ivoire, Kenya, Malawi, Mozambique, Nigeria, Uganda, and Tanzania.

Via Stocktwits

Topics Death Government

$1,000 in VEA Could Turn Into $57,000 ↗

July 08, 2025

Via The Motley Fool

Topics ETFs Economy

Alphabet-Backed Drug Discovery Firm Nears Human Trials Of AI-Developed Remedies, Says President: 'The Next Big Milestone Is...' ↗

July 07, 2025

Isomorphic Labs, a subsidiary of Alphabet Inc., is close to human trials for its AI-designed medicines. Other companies are also racing to use AI in drug discovery.

Via Benzinga

Topics Artificial Intelligence

Better Dividend ETF to Buy for Passive Income: SCHD or GCOW ↗

July 03, 2025

Via The Motley Fool

Topics ETFs Stocks

< Previous 1 2

...

7 8 9 10 11 12 13 14 15

...

57 58 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Round 2 of the Cappies is Live! Vote Now.

Novartis AG Common Stock (NY:NVS)

All News about Novartis AG Common Stock

The Newspapers of New England Family

We continue to need local support from our readers

Round 2 of the Cappies is Live! Vote Now.

Novartis AG Common Stock (NY:NVS)

All News about Novartis AG Common Stock

Enjoying the Concord Monitor?

Sign in